CAR T-cell Therapy for Blood Cancers in Young People

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Recruiting Observational Study
Lymphoma Leukemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 and older
Sex
Any
Study type
Observational
Participants needed
60 (estimated)
Sponsor
National Cancer Institute (NCI) · NIH
Who this trial is looking for

This trial is looking for children and young adults aged 5 to 35 who have blood cancer that is not responding to previous treatments. Participants will undergo tests to see how CAR T-cell therapy may affect their thinking and memory skills.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am aged between 5 and 35 years old.
  • I have been diagnosed with relapsed or refractory leukemia or lymphoma.
  • I will receive CAR T-cell therapy.
  • I can speak and understand English or Spanish.
  • I have a caregiver who can support me during the study.
  • I have access to a computer or tablet with a camera and internet.
  • I am willing to sign a consent document.

You may not be able to join if

  • I have a pre-existing global intellectual disability.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills. Object…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: * Participants with disease * Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites * For participants enrolled on a CAR T-cell treatment protocol, data sharing for the pu…
Contacts

NCI Ped LeukemiaLymph Cell Tx Tm

(240) 760-6970

ncilltct@mail.nih.gov

CONTACT

Pamela L Wolters, Ph.D.

(240) 760-6035

woltersp@mail.nih.gov

CONTACT